• Japanese
  • Korean
  • Chinese
Cover Image

Hepatitis Drugs and Vaccines: World Market 2013-2023

Your guide to sales outlooks and R&D for hepatitis treatments

Where are hepatitis medicines going? Visiongain's updated report predicts revenues there from 2013 to 2023. It also explains trends in that business and technology - with prospects and opportunities - to help your work.

In that study you gain sales forecasts at overall world market, submarket, product, and national level. See what's happening. Also discover what has most growth potential.

Read on, then, to explore that industry and see what its future market could be worth.

Forecasts to 2023 and other analyses show you commercial potentials

Besides revenue forecasting, our new work shows historical data, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and research developments (R&D). You also get 77 tables, 66 charts, and an interview.

Is finding data for anti-hepatitis products a challenge? Avoid falling behind. You can now stay ahead in knowledge, benefiting your research, analyses, and decisions. Also save time.

There you investigate the future of hepatitis medicine. You discover what's happening and see where the money lies. Finding that antiviral data just got easier.

Anyhow, the following sections show what you get in our new research and analysis.

Discover prospects for the world market and submarkets

Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of four hepatitis treatment submarkets:

  • Oral antivirals
  • Interferons
  • Vaccines
  • Other agents.

How will the hepatitis drugs and vaccines market expand? Which parts will most prosper? There you assess potential for sales and revenue growth.

Also our study discusses what stimulates and restrains that market. That analysis helps you identify potential and find ways for your business to benefit.

You also find revenue predictions for brands.

See forecasts for 10 leading anti-hepatitis products

How will those antiviral brands perform to 2023 at world level? Our study forecasts individual revenues of 10 top products:

  • Baraclude
  • Zeffix
  • Hepsera
  • Viread
  • Tyzeka
  • Engerix-B/Havrix/Twinrix/Fendrix
  • Pegasys
  • Incivek
  • PegIntron
  • Victrelis.

There you discover how high sales can go, to 2023, finding products and years with highest predicted growth and revenues. Also you compare competitors. You see what's happening, then, understanding trends, competition, challenges, and opportunities.

Our report also divides its overall world forecast into geographical regions.

What prospects for regions and countries?

Developments worldwide expand the hepatitis products market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.

In developed and developing countries, opportunities for pharmaceutical companies will occur from 2013 to 2023. See where and how.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:

  • United States (US)
  • Japan
  • EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
  • BRIC countries - Brazil, Russia, India, and China.

There you discover progress and outlooks. In particular, drug and vaccine launches from 2013 to 2023 will change medical prescribing and the commercial landscape. See how.

Research and development - assess innovation, trends, and possibilities

What about R&D - pipelines for new drugs and vaccines? You assess trends there, including these:

  • Cyclophilin inhibition
  • Protease inhibition
  • All-oral agents
  • Agents with potential roles in hep-C/HIV co-infection
  • Nucleoside and non-nucleoside polymerase inhibition
  • Therapeutic vaccines
  • Combination regimens.

R&D for hepatitis medicine holds strength, variety, and promise. You assess innovations there, hearing about developments and finding their significance. Discover progress.

For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing progress to help your work. See, then, what the future holds.

Prominent companies and 2017 market value

What happens next? From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our report predicts the world market for anti-hepatitis drugs and vaccines will reach $15.25bn in 2017, and expand further to 2023.

Our work shows you what activities, technologies, and organisations there hold potential. Its analyses cover prominent companies, including these:

  • Roche
  • GSK
  • Bristol-Myers Squibb
  • Merck & Co.
  • Vertex Pharmaceuticals
  • Gilead Sciences
  • Novartis.

Prospects for R&D are strong, and from 2013 there will arise many opportunities. Our analysis shows you possibilities, helping you stay ahead.

Nine ways Hepatitis Drugs and Vaccines: World Market 2013-2023 helps you

To sum up, our investigation gives you the following knowledge:

  • Revenue to 2023 of the world market for anti-hepatitis products - discover that industry's overall sales potential
  • Revenues to 2023 for 4 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and revenues
  • Revenues to 2023 for 10 products - find sales outlooks for top brands, seeing how they can compete and succeed
  • Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth
  • Assessments of 11 companies - hear about participants' activities, capabilities, results, and outlooks
  • Review of R&D - explore progress in research and development, finding technological and medical possibilities
  • Competition and opportunities - investigate what shapes that market's future, including ways to develop business
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages
  • Prospects for established competitors and firms seeking to enter that sector - explore needs, practices and outlooks for future success.

You gain information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Assess the potential of those antiviral agents now, seeing what you can gain.

Table of Contents

1. Executive Summary

  • 1.1 Hepatitis Treatments and Vaccines: World Market Overview
  • 1.2 Chapter Breakdown
  • 1.3 Research and Analysis Methods

2. Introduction to Hepatitis and its Treatments

  • 2.1 What is Hepatitis?
  • 2.2 Diagnosing Hepatitis: The Asymptotic Nature of the Disease
  • 2.3 How is Hepatitis Classified?
    • 2.3.1 Hepatitis A
    • 2.3.2 Hepatitis B
    • 2.3.3 Hepatitis C
    • 2.3.4 Hepatitis D
    • 2.3.5 Hepatitis E
  • 2.4 Risk Factors for Hepatitis
  • 2.5 Incidence and Prevalence Patterns in Hepatitis
  • 2.6 Hepatitis: Treatment and Prevention
    • 2.6.1 Antivirals: Inhibiting Viral Replication
      • 2.6.1.1 Reverse Transcriptase Inhibitors
      • 2.6.1.2 Protease Inhibitors
    • 2.6.2 Interferons: Dual Mode of Action
      • 2.6.2.1 Combination Therapy: Treatment with Interferon and Antivirals
    • 2.6.3 Vaccines: The Immunotherapeutic Approach
      • 2.6.3.1 Hepatitis E Vaccine: Raising Hopes for an Overlooked Subtype

3. World Hepatitis Treatments and Vaccines Market, 2013-2023

  • 3.1 The Hepatitis Treatments and Vaccines Market, 2012
    • 3.1.1 The Hepatitis Treatment Market by Indication, 2012
  • 3.2 The Hepatitis Treatments and Vaccines Market: Revenue Forecast, 2013-2023
    • 3.2.1 Rising Awareness and Screening: Expanding Treatment Population
    • 3.2.2 Generic Competition in the Hepatitis B Treatment Market
    • 3.2.3 Biosimilar Interferons: A New Era in Hepatitis Treatment?
    • 3.2.4 Direct-Acting Antivirals (DAAs): A Change in Therapeutic Landscape
      • 3.3 Oral Antivirals Submarket, 2012
    • 3.3.1 DAAs in Hepatitis B
    • 3.3.2 DAAs in Hepatitis C
    • 3.3.3 Oral Antivirals Submarket: Revenue Forecast, 2013-2023
    • 3.3.4 Strong Developmental Pipeline to Drive Market Growth
    • 3.3.5 All-Oral Treatments for Hepatitis C: Improving Tolerability
  • 3.4 Interferons Submarket, 2012
    • 3.4.1 Standard of Care for Hepatitis C
    • 3.4.2 Drawbacks to Interferon Therapy
    • 3.4.3 Declining Revenues 2008-2011
    • 3.4.4 Interferons Submarket: Revenue Forecast, 2013-2023
    • 3.4.5 Next Generation Interferons: A Potential Advance or Lateral Move?
  • 3.5 Hepatitis Vaccines Submarket, 2012
    • 3.5.1 GSK: A Dominant Global Player
    • 3.5.2 Expanding Vaccination Programmes in Emerging Markets
    • 3.5.3 Hepatitis Vaccines Submarket: Revenue Forecast, 2013-2023
  • 3.6 Hepatitis Treatments and Vaccines: Submarket Shares 2012, 2018 and 2023
  • 3.7 Hepatitis Treatment Market: Revenue Forecast by Indication, 2013-2023

4. Leading National Hepatitis Treatments and Vaccines Markets, 2013-2023

  • 4.1 Global Prevalence of Hepatitis, 2012
    • 4.1.1 The Importance of Asia
  • 4.2 Hepatitis Treatments and Vaccines Market: Regional Breakdown, 2012
  • 4.3 Hepatitis Treatments and Vaccines Market: Regional Forecast, 2013-2023
  • 4.4 The US
    • 4.4.1 Population Movement and Hepatitis
    • 4.4.2 Increased Screening towards Target Population
    • 4.4.3 The US: Revenue Forecast, 2013-2023
  • 4.5 Leading EU Markets for Hepatitis Treatments and Vaccines
    • 4.5.1 Regional Prevalence
    • 4.5.2 EU5 Market, 2012
    • 4.5.3 EU5: Revenue Forecasts, 2013-2023
    • 4.5.4 Italy: Revenue Forecast, 2013-2023
    • 4.5.5 Spain: Revenue Forecast, 2013-2023
    • 4.5.6 Germany: Revenue Forecast, 2013-2023
    • 4.5.7 UK: Revenue Forecast, 2013-2023
    • 4.5.8 France: Revenue Forecast, 2013-2023
  • 4.6 Hepatitis in Asia
  • 4.7 China
    • 4.7.1 Increased Vaccination
    • 4.7.2 Rising Middle Class
    • 4.7.3 Hepatitis C Outbreaks
    • 4.7.4 Domestic Drug and Vaccine Development
    • 4.7.5 China: Revenue Forecast, 2013-2023
  • 4.8 Japan
    • 4.8.1 Hepatitis B and C in Japan
    • 4.8.2 Japan: Revenue Forecast, 2013-2023
  • 4.9 India
    • 4.9.1 Low Awareness and Vaccination Rates
    • 4.9.2 India: Revenue Forecast, 2013-2023
  • 4.10 Russia
    • 4.10.1 Low Treatment Rate and High Drug Costs Limiting Market
    • 4.10.2 Russia: Revenue Forecast, 2013-2023
  • 4.11 Brazil
    • 4.11.1Current Disease Prevalence
    • 4.11.2 Brazil: Revenue Forecast, 2013-2023

5. Leading Hepatitis Therapies: Market Prospects to 2023

  • 5.1 Leading Hepatitis B Therapies, 2013-2023
  • 5.2 Baraclude (Bristol-Myers Squibb)
    • 5.2.1 Recent Revenue Analysis
    • 5.2.2 Global Patent Challenges Will Hit Future Revenues
    • 5.2.3 Baraclude: Revenue Forecast, 2013-2023
  • 5.3 Zeffix (GSK)
    • 5.3.1 Recent Revenue Analysis
    • 5.3.2 Increasing Drug Resistance with Continued Use
    • 5.3.3 Launch of Generic Versions Will Affect Drug Revenues
    • 5.3.4 Zeffix: Revenue Forecast, 2013-2023
  • 5.4 Hepsera (Gilead Sciences/GSK)
    • 5.4.1 Recent Revenue Analysis
    • 5.4.2 Patent Extension Approved Until 2016
    • 5.4.3 Switching to Viread Will Limit Hepsera Revenues
    • 5.4.4 Hepsera: Revenue Forecast, 2013-2023
  • 5.5 Viread (Gilead Sciences)
    • 5.5.1 Recent Revenue Analysis
    • 5.5.2 GSK Alliance: Targeting Emerging Asian Markets
    • 5.5.3 Competition with Viread Pro-drugs may Harm Drug Revenues
    • 5.5.4 Viread: Revenue Forecast, 2013-2023
  • 5.6 Tyzeka (Novartis)
    • 5.6.1 Lack of Differentiation and Competition Affecting Market Share
    • 5.6.2 Tyzeka: Revenue Forecast, 2013-2023
  • 5.7 Leading Hepatitis B Vaccines, 2013-2023
  • 5.8 Engerix-B/Havrix/Twinrix/Fendrix (GSK)
    • 5.8.1 Recent Revenue Analysis
    • 5.8.2 Demand and Supply in Emerging Markets
    • 5.8.3 Pipeline Compounds Will Provide Strong Competition
    • 5.8.4 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast, 2013-2023
  • 5.9 Leading Hepatitis C Therapies, 2013-2023
  • 5.10 Pegasys (Roche)
    • 5.10.1 Recent Revenue Analysis
    • 5.10.2 Label Expansions and Lifecycle Management Strategies
    • 5.10.3 Pegasys: Revenue Forecast, 2013-2023
  • 5.11 Incivek (Vertex Pharmaceuticals/J&J/Mitsubishi Tanabe)
    • 5.11.1 Recent Revenue Analysis
    • 5.11.2 Targeting Hep-C/HIV Co-Infected Patients
    • 5.11.3 Incivek in Interferon-Free Regimens
    • 5.11.4 Pipeline Competition May Affect Revenues
    • 5.11.5 Incivek: Revenue Forecast, 2013-2023
  • 5.12 PegIntron (Merck & Co.)
    • 5.12.1 Recent Revenue Analysis
    • 5.12.2 Competition from Interferon Biosimilars
    • 5.12.3 Enhancing Drug Lifecycle
    • 5.12.4 PegIntron: Revenue Forecast, 2013-2023
  • 5.13 Victrelis (Merck & Co.)
    • 5.13.1 Recent Revenue Analysis
    • 5.13.2 Roche Collaboration
    • 5.13.3 Product Differentiation
    • 5.13.4 Victrelis: Revenue Forecast, 2013-2023

6. Hepatitis Treatments and Vaccines Market: Leading Pipeline Candidates

  • 6.1 Leading Hepatitis C Pipeline Candidates, 2012
    • 6.1.1 Alisporivir (Novartis/Debiopharm): Advanced Cyclophilin Inhibitor
    • 6.1.2 BI 201335 (Boehringer Ingelheim): Fast-Tracked Protease Inhibitor
    • 6.1.2.1 BI 207127 (Boehringer Ingelheim): First All-Oral Hep C Drug?
    • 6.1.3 Daclatasvir (Bristol-Myers Squibb): Potential Role in Hep-C/HIV Co-Infection?
    • 6.1.3.1 Asunaprevir (Bristol-Myers Squibb): Synergistic Effect with Daclatasvir
    • 6.1.4 GS-7977 (Sofosbuvir; Gilead Sciences): Progression to Phase III
    • 6.1.5 TMC435 (Tibotec Pharmaceuticals/Medivir): Next Generation Protease Inhibitor
      • 6.1.5.1 TMC435 in All-Oral Regimens
    • 6.1.6 Vaniprevir (Merck & Co.): Patent Security Till 2027
    • 6.1.7 ABT-450 (Abbott Laboratories): Fast-Tracked Into Phase III
    • 6.1.8 ACH-1625 (Achillion Pharmaceuticals): Playing Catch Up?
      • 6.1.8.1 ACH-2684 (Achillion Pharmaceuticals)
      • 6.1.8.2 ACH-2928 (Achillion Pharmaceuticals)
    • 6.1.9 ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals): Therapeutic Vaccine in Phase II Trials
    • 6.1.10 Danoprevir (Roche): Testing Out Combination Regimens
    • 6.1.11 GI-5005 (GlobeImmune): Yeast-based Hep C Vaccine
    • 6.1.12 IDX184 (Idenix Pharmaceuticals): Development Ceased
    • 6.1.13 INX-189 (Bristol-Myers Squibb): Cardiovascular Effects May Halt Development
    • 6.1.14 Locteron (Biolex): Controlled Release Formulation
    • 6.1.15 Peginterferon Lambda-1a (Bristol-Myers Squibb): Improved Side Effect Profile
    • 6.1.16 R7128 (Roche/Pharmasset): Broad Spectrum Treatment
    • 6.1.17 SCY-635 (SCYNEXIS)
    • 6.1.18 Setrobuvir (Roche): Fast-Tracked Polymerase Inhibitor
    • 6.1.19 Tegobuvir (Gilead Sciences): Combination Therapy in Peginterferon-free Regimens
    • 6.1.20 VX-222 (Vertex Pharmaceuticals): Landmark Interferon-Free Drug Regimen
  • 6.2 Leading Hepatitis B Pipeline Candidates, 2012
    • 6.2.1 Heplisav (Dynavax Technologies): Higher Seroprotection Levels
    • 6.2.2 Rep 9AC' (REPLICor): Targeting Hb Surface Antigens
    • 6.2.3 Myrcludex B (MYR): Dual Effect on Hepatitis B and D
    • 6.2.4 AGX-1009 (Agenix): Tenofovir Prodrug Targeted towards China's Growing Hepatitis Population

7. Leading Companies in the Hepatitis Treatments and Vaccines Market

  • 7.1 Leading Market Players, 2012
  • 7.2 Roche
    • 7.2.1 Product Overview and Performance, 2012
    • 7.2.2 Recent Developments: Partnership with Anadys
    • 7.2.3 Hepatitis Pipeline
    • 7.2.4 Future Outlook: Slowing Demand May Affect Market Dominance
  • 7.3 GSK
    • 7.3.1 Product Overview and Performance, 2012
    • 7.3.2 Recent Developments: Increasing Focus on Novel Small Molecule Therapies
    • 7.3.3 Hepatitis Pipeline: Polymerase Inhibitor in Phase II
    • 7.3.4 Future Outlook: Dominance in Vaccines Unmatched
  • 7.4 Bristol-Myers Squibb
    • 7.4.1 Product Overview and Performance, 2012
    • 7.4.2 Recent Developments: Strengthening Product Pipeline Through Acquisitions
    • 7.4.2.1 Bristol-Myers Squibb Acquires Inhibitex
    • 7.4.3 Hepatitis Pipeline: Strong Future Position in Hepatitis C
    • 7.4.4 Future Outlook: Market Set For Intense Competition
  • 7.5 Merck & Co.
    • 7.5.1 Product Overview and Performance, 2012
    • 7.5.2 Recent Developments: Discovering Combination Treatments Through Roche Partnership
    • 7.5.3 Hepatitis Pipeline
    • 7.5.4 Future Outlook: Company Pins Hopes on Victrelis and Launch of Pipeline Therapies
  • 7.6 Vertex Pharmaceuticals
    • 7.6.1 Product Overview and Performance, 2012
    • 7.6.2 Recent Developments
    • 7.6.3 Hepatitis Pipeline: Polymerase Inhibitors in Phase II Trials
    • 7.6.4 Future Outlook: Company Hope Pipeline Will Maintain Market Position
  • 7.7 Gilead Sciences
    • 7.7.1 Product Overview and Performance, 2012
    • 7.7.2 Recent Developments: Gilead Acquires Pharmasset
    • 7.7.3 Hepatitis Pipeline: Strong and Diverse
    • 7.7.4 Future Outlook: Strongest Pipeline Than Any Other Company
  • 7.8 Novartis
    • 7.8.1 Product Overview and Performance, 2012
    • 7.8.2 Recent Developments: Company Partnerships/Collaborations to Strengthen Position
    • 7.8.3 Hepatitis Pipeline: Improved Cyclophilin Inhibitor in Phase III Trials
    • 7.8.4 Future Outlook
  • 7.9 Leading Hepatitis Pipeline Companies, 2012
    • 7.9.1 Abbott Laboratories: New Venture into Hepatitis
    • 7.9.2 Achillion Pharmaceuticals: Next Target for Acquisition?
      • 7.9.2.1 Achillion and Gilead
    • 7.9.3 Boehringer Ingelheim: Focus on Protease/Polymerase Inhibitors
    • 7.9.4 Idenix Pharmaceuticals: Pipeline Drug Receives Fast-Track Status
      • 7.9.4.1 Idenix Pharmaceuticals: Outlook

8. Hepatitis Treatments and Vaccines Market: Industry Trends, 2013-2023

  • 8.1 Strengths and Weaknesses in the Hepatitis Treatments and Vaccines Market, 2013-2023
    • 8.1.1 Resistance in Hepatitis B
    • 8.1.2 Interferon Therapy Has Drawbacks
    • 8.1.3 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C
  • 8.2 Opportunities and Threats in the Hepatitis Treatments and Vaccines Market, 2013-2023
    • 8.2.1 Hepatitis Screening and Diagnosis
    • 8.2.2 Raising Awareness and Overcoming Social Stigma
    • 8.2.3 Personalised Therapy
    • 8.2.4 HIV Co-Infection
    • 8.2.5 Asia
  • 8.3 STEP Analysis of the World Hepatitis Treatments and Vaccines Market, 2013-2023
    • 8.3.1 Social Development
      • 8.3.1.1 Social Implications in China
    • 8.3.2 Technological Advances
    • 8.3.3 Economic Pressures
    • 8.3.4 Political Issues
  • 8.4 Hepatitis B Vaccination
  • 8.5 Limited Hepatitis B Pipeline
  • 8.6 Hepatitis C Vaccines
  • 8.7 Oral Direct-Acting Antivirals
    • 8.7.1 Nucleoside and Non-Nucleoside Polymerase Inhibitors
    • 8.7.2 Combining Protease and Polymerase Inhibitors
    • 8.7.3 The Need for Ribavirin
    • 8.7.4 Twelve Week Treatment Target
  • 8.8 Pharmaceutical Investment in Hepatitis C
    • 8.8.1 Licensing and Partnering Deals
    • 8.8.2 Acquisitions in Hepatitis C
    • 8.8.3 Future Targets for Collaboration or Acquisition

9. Research Interview

  • 9.1 Interview with Mr Carl Stubbings, CBO, Benitec Pharma Ltd.
    • 9.1.1 The Hepatitis C Treatment Market Landscape
    • 9.1.2 TT-034: Cassette Vector for the Treatment of Hepatitis C
    • 9.1.3 The Future Hepatitis Drug Market

10. Conclusions

  • 10.1 State of the Hepatitis Treatments and Vaccines Market, 2012
  • 10.2 Growth in the Hepatitis Treatments and Vaccines Market, 2013-2023
    • 10.2.1 Rise of Direct-Acting Antivirals in Hepatitis C
    • 10.2.2 Weak Pipeline for Hepatitis B
  • 10.3 Asia as a Hepatitis Drug Market

List of Tables

  • Table 1.1 Currency Exchange Rates
  • Table 1.2 Abbreviations and Acronyms Used in the Report
  • Table 2.1 Hepatitis Subtypes: An Overview
  • Table 2.2 Polymerase Inhibitors Approved for Hepatitis B in the US and EU, 2012
  • Table 3.1 Hepatitis Treatments and Vaccines: Revenue ($bn) and Market Share (%) by Sector, 2012
  • Table 3.2 Hepatitis Treatment Market: Revenue ($bn) and Market Share (%) by Indication, 2012
  • Table 3.3 Hepatitis Treatments and Vaccines: Overall Market and Revenue Forecasts ($bn) by Sector, 2013-2023
  • Table 3.4 Selected Biosimilar Interferon Alpha Therapies Approved in Emerging Markets, 2013
  • Table 3.5 Oral Antivirals Submarket: Revenue ($bn) and Market Share (%) by Drug, 2012
  • Table 3.6 Oral Antivirals Submarket: Revenue Forecast ($bn), 2013-2023
  • Table 3.7 Interferons Submarket: Revenue ($bn) and Market Share (%) by Drug, 2012
  • Table 3.8 Interferons Submarket: Revenue Forecast ($bn), 2013-2023
  • Table 3.9 Vaccines Submarket: Revenue ($bn) and Market Share (%) by Drug, 2012
  • Table 3.10 Vaccines Submarket: Revenue Forecast ($bn), 2013-2023
  • Table 3.11 Hepatitis Treatments and Vaccines: Revenue ($bn) and Market Share (%) by Sector in 2012, 2018 and 2023
  • Table 3.12 Hepatitis Treatment Market: Overall Market and Revenue Forecasts ($bn) by Indication, 2013-2023
  • Table 4.1 Chronic Hepatitis B & C: Global Prevalence (millions) by Region, 2012
  • Table 4.2 Hepatitis Treatments and Vaccines: Revenue ($bn) and Market Share (%) by Region, 2012
  • Table 4.3 Hepatitis Treatments and Vaccines: Overall Market and Revenue Forecasts ($bn) by Region, 2013-2023
  • Table 4.4 US Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
  • Table 4.5 EU5 Hepatitis Treatments and Vaccines: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2012
  • Table 4.6 EU5 Hepatitis Treatments and Vaccines Market: Revenue Forecasts ($bn) by Country, 2013-2023
  • Table 4.7 Italian Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
  • Table 4.8 Spanish Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
  • Table 4.9 German Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
  • Table 4.10 UK Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
  • Table 4.11 French Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
  • Table 4.12 Chinese Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
  • Table 4.13 Japanese Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
  • Table 4.14 Indian Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
  • Table 4.15 Russian Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
  • Table 4.16 Brazilian Hepatitis Treatments and Vaccines: Forecast ($bn), 2013-2023
  • Table 5.1 Baraclude: Key Facts, 2012
  • Table 5.2 Baraclude: Revenue ($bn) by Region, 2010-2012
  • Table 5.3 Baraclude: Revenue Forecast ($bn), 2013-2023
  • Table 5.4 Zeffix: Key Facts, 2012
  • Table 5.5 Zeffix: Revenue ($bn) by Region, 2011-2012
  • Table 5.6 Zeffix: Revenue Forecast ($bn), 2013-2023
  • Table 5.7 Hepsera: Key Facts, 2012
  • Table 5.8 Hepsera: Revenue ($bn) by Company, 2010-2012
  • Table 5.9 Hepsera: Revenue Forecast ($bn), 2013-2023
  • Table 5.10 Viread: Key Facts, 2012
  • Table 5.11 Viread: Revenue Forecast ($bn), 2013-2023
  • Table 5.12 Tyzeka: Key Facts, 2012
  • Table 5.13 Tyzeka: Revenue Forecast ($bn), 2013-2023
  • Table 5.14 GSK's Hepatitis Vaccines: Key Facts, 2012
  • Table 5.15 Engerix-B/Havrix/Twinrix/Fendrix: Revenue ($bn) and Market Share (%) by Region, 2012
  • Table 5.16 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast ($bn), 2013-2023
  • Table 5.17 Pegasys: Key Facts, 2012
  • Table 5.18 Pegasys: Revenue Forecast ($bn), 2013-2023
  • Table 5.19 Incivek: Key Facts, 2012
  • Table 5.20 Incivek: Revenue ($bn) and Market Share (%) by Region, 2012
  • Table 5.21 Incivek: Revenue Forecast ($bn), 2013-2023
  • Table 5.22 PegIntron: Key Facts, 2012
  • Table 5.23 PegIntron: Revenue Forecast ($bn), 2013-2023
  • Table 5.24 Victrelis: Key Facts, 2012
  • Table 5.25 Victrelis: Revenue Forecast ($bn), 2013-2023
  • Table 6.1 Selected Hepatitis C Pipeline Candidates in Phase II & III, 2012
  • Table 6.2 Alisporivir: Phase III Trials, 2012
  • Table 6.3 Selected Hepatitis B Pipeline Candidates in Clinical Trials, 2012
  • Table 7.1 Hepatitis Treatments and Vaccines: Revenue ($bn) and Market Share (%) by Company, 2012
  • Table 7.2 Roche: Hepatitis Pipeline, 2012
  • Table 7.3 Pegasys: Revenue ($bn) and Market Share (%) in 2012, 2018 and 2023
  • Table 7.4 GSK Pharmaceuticals: Revenue ($bn) and Market Share (%) by Therapeutic Area, 2012
  • Table 7.5 Bristol-Myers Squibb: Hepatitis Pipeline, 2012
  • Table 7.6 Merck & Co: Revenue ($bn) and Market Share (%) by Therapeutic Area, 2012
  • Table 7.7 Telaprevir: Revenue ($bn) by Trade Name, 2012
  • Table 7.8 Gilead Sciences: Revenue ($bn) and Market Share (%) by Therapeutic Area, 2012
  • Table 7.9 Gilead Sciences: Hepatitis Pipeline, 2012
  • Table 7.10 Achillion Pharmaceuticals: Hepatitis Pipeline, 2012
  • Table 7.11 Idenix Pharmaceuticals: Hepatitis Pipeline, 2012
  • Table 8.1 Hepatitis Treatments and Vaccines Market: Strengths and Weaknesses, 2013
  • Table 8.2 Hepatitis Treatments and Vaccines Market: Opportunities and Threats, 2013-2023
  • Table 8.3 Liver Cancer: Global Deaths (per 100,000) by Region, 2008
  • Table 8.4 Selected Pipeline Drugs Granted Fast Track Status, 2011-2012
  • Table 8.5 Selected All-Oral Hepatitis C Regimens in Development, 2012
  • Table 8.6 Market Capitalisation of Selected Hepatitis Drug Developers, 2012
  • Table 10.1 Hepatitis Treatments and Vaccines: Revenue ($bn) by Drug & Sector in 2012, 2018 & 2023
  • Table 10.2 Leading Hepatitis Treatments: Patent Expiries & Peak Revenues ($bn)

List of Figures

  • Figure 2.1 Brief History of Hepatitis, 1947-2012
  • Figure 3.1 Hepatitis Treatments and Vaccines: Market Share (%) by Sector, 2012
  • Figure 3.2 Hepatitis Treatment Market: Market Share (%) by Indication, 2012
  • Figure 3.3 Hepatitis Treatments and Vaccines: Overall Market Forecast ($bn), 2013-2023
  • Figure 3.4 Oral Antivirals Submarket: Market Share (%) by Drug, 2012
  • Figure 3.5 Oral Antivirals Submarket: Revenue Forecast ($bn), 2013-2023
  • Figure 3.6 Oral Antivirals Submarket: Drivers and Restraints, 2013-2023
  • Figure 3.7 Interferons Submarket: Market Share (%) by Drug, 2012
  • Figure 3.8 Interferons Submarket: Revenue Forecast ($bn), 2013-2023
  • Figure 3.9 Interferons Submarket: Drivers and Restraints, 2013-2023
  • Figure 3.10 Vaccines Submarket: Market Share (%) by Drug, 2012
  • Figure 3.11 Vaccines Submarket: Revenue Forecast ($bn), 2013-2023
  • Figure 3.12 Vaccines Submarket: Drivers and Restraints, 2013-2023
  • Figure 3.13 Hepatitis Treatments and Vaccines: Market Share (%) by Sector, 2018
  • Figure 3.14 Hepatitis Treatments and Vaccines: Market Share (%) by Sector, 2023
  • Figure 3.15 Hepatitis B Submarket: Revenue Forecast ($bn), 2013-2023
  • Figure 3.16 Hepatitis B Submarket: Drivers and Restraints, 2013-2023
  • Figure 3.17 Hepatitis C Submarket: Revenue Forecast ($bn), 2013-2023
  • Figure 3.18 Hepatitis C Submarket: Drivers and Restraints, 2013-2023
  • Figure 4.1 Chronic Hepatitis B: Global Prevalence (%) by Region, 2012
  • Figure 4.2 Chronic Hepatitis C: Global Prevalence (%) by Region, 2012
  • Figure 4.3 Hepatitis Treatments and Vaccines: Market Share (%) by Region, 2012
  • Figure 4.4 Hepatitis Treatments and Vaccines: Market Share (%) by Region, 2018
  • Figure 4.5 Hepatitis Treatments and Vaccines: Market Share (%) by Region, 2023
  • Figure 4.6 US Hepatitis Treatments and Vaccines: Submarket Forecast ($bn), 2013-2023
  • Figure 4.7 EU5 Hepatitis Treatments and Vaccines: Market Share (%) by Country, 2012
  • Figure 4.8 EU5 Hepatitis Treatments and Vaccines: Submarket Forecast ($bn), 2013-2023
  • Figure 4.9 Italian Hepatitis Treatments and Vaccines: Submarket Forecast ($bn), 2013-2023
  • Figure 4.10 Spanish Hepatitis Treatments and Vaccines: Submarket Forecast ($bn), 2013-2023
  • Figure 4.11 German Hepatitis Treatments and Vaccines: Submarket Forecast ($bn), 2013-2023
  • Figure 4.12 UK Hepatitis Treatments and Vaccines: Submarket Forecast ($bn), 2013-2023
  • Figure 4.13 French Hepatitis Treatments and Vaccines: Submarket Forecast ($bn), 2013-2023
  • Figure 4.14 Chinese Hepatitis Treatments and Vaccines: Submarket Forecast ($bn), 2013-2023
  • Figure 4.15 Japanese Hepatitis Treatments and Vaccines: Submarket Forecast ($bn), 2013-2023
  • Figure 4.16 Indian Hepatitis Treatments and Vaccines: Submarket Forecast ($bn), 2013-2023
  • Figure 4.17 Russian Hepatitis Treatments and Vaccines: Submarket Forecast ($bn), 2013-2023
  • Figure 4.18 Brazilian Hepatitis Treatments and Vaccines: Submarket Forecast ($bn), 2013-2023
  • Figure 5.1 Baraclude: Revenue ($bn) by Region, 2010-2012
  • Figure 5.2 Baraclude: Revenue Forecast ($bn), 2013-2023
  • Figure 5.3 Zeffix: Revenue Share (%) by Region, 2012
  • Figure 5.4 Zeffix: Revenue Forecast ($bn), 2013-2023
  • Figure 5.5 Hepsera: Revenue ($bn) by Company, 2010-2012
  • Figure 5.6 Hepsera: Revenue Forecast ($bn), 2013-2023
  • Figure 5.7 Viread: Revenue Forecast ($bn), 2013-2023
  • Figure 5.8 Tyzeka: Revenue ($bn), 2010-2012
  • Figure 5.9 Tyzeka: Revenue Forecast ($bn), 2013-2023
  • Figure 5.10 Engerix-B/Havrix/Twinrix/Fendrix: Market Share (%) by Region, 2012
  • Figure 5.11 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast ($bn), 2013-2023
  • Figure 5.12 Pegasys: Revenue ($bn), 2010-2012
  • Figure 5.13 Pegasys: Revenue Forecast ($bn), 2013-2023
  • Figure 5.14 Incivek: Market Share (%) by Region, 2012
  • Figure 5.15 Incivek: Revenue Forecast ($bn), 2013-2023
  • Figure 5.16 PegIntron: Revenue Forecast ($bn), 2013-2023
  • Figure 5.17 Victrelis: Revenue Forecast ($bn), 2013-2023
  • Figure 7.1 Hepatitis Treatments and Vaccines: Market Share (%) by Company, 2012
  • Figure 7.2 Pegasys: Revenue ($bn) in 2012, 2018 and 2023
  • Figure 7.3 Roche: Key Events in the Hepatitis Market, 2012-2022
  • Figure 7.4 GSK Pharmaceuticals: Market Share (%) by Therapeutic Area, 2012
  • Figure 7.5 Bristol-Myers Squibb: Key Events in the Hepatitis Market, 2012-2022
  • Figure 7.6 Merck & Co: Market Share (%) by Therapeutic Area, 2012
  • Figure 7.7 Telaprevir: Revenue ($bn) by Trade Name, 2011-2012
  • Figure 7.8 Gilead Sciences: Market Share (%) by Therapeutic Area, 2012
  • Figure 7.9 Gilead Sciences: Key Events in the Hepatitis Market, 2012-2022
  • Figure 8.1 Liver Cancer: Incidence and Mortality Rates Per 100,000 population, by Region, 2008
  • Figure 8.2 All-Oral Regimens: Projected Launches, 2012-2016
  • Figure 10.1 Hepatitis Treatments and Vaccines: Revenue ($bn) by Sector in 2012, 2018 & 2023

Companies Listed

  • 3SBio
  • Abbott Laboratories
  • Abbott Molecular
  • Achillion Pharmaceuticals
  • Agenix
  • Alios BioPharma
  • American University in Cairo
  • Anadys Pharmaceuticals (now part of Roche)
  • Anhui Biochem Bio-Pharmaceutical
  • Apotex
  • Aurobindo Pharma
  • Beijing Key Yuan Xinhai Pharmaceutical
  • Beijing Wantai Biological Pharmacy Enterprise
  • Benitec Biopharma
  • BioCryst Pharmaceuticals
  • Biogen Idec
  • Biolex
  • BioLineRx
  • BioPhausia (now part of Medivir)
  • Biota Holdings
  • Biotechnology Enterprise Management
  • Boehringer Ingelheim
  • Bristol-Myers Squibb (BMS)
  • Centers for Disease Control and Prevention (CDC) [US]
  • China NT Pharma Group
  • Chinese Foundation for Hepatitis Prevention and Control (CFHPC)
  • Chiron (now part of Novartis)
  • ChronTech Pharma
  • Chugai Pharmaceutical (part of Roche)
  • Codexis
  • Compass Biotechnologies
  • Corvas International (now part of Dendreon)
  • CPP Investment Board
  • Debiopharm
  • Dendreon
  • Drug Controller General of India (DCGI)
  • Dynavax Technologies
  • Eli Lilly
  • EMA Committee for Medicinal Products for Human Use (CHMP) [EU]
  • Enanta Pharmaceuticals
  • European Association for the Study of the Liver (EASL)
  • European Commission (EC)
  • European Liver Patients Association (ELPA)
  • European Medicines Agency (EMA)
  • Feron
  • Food and Drug Administration (FDA) [US]
  • Genelabs Technologies (now part of GSK)
  • Genoscience
  • Getz Pharma
  • Gilead Sciences
  • GlobeImmune
  • GSK
  • Hainan Zhonghe Pharmaceutical
  • Health Protection Agency (HPA) [UK]
  • Hepatera
  • High-Tech Gründerfonds
  • Hualida Biotech
  • Idenix Pharmaceuticals
  • Imperial College London
  • Inhibitex (now part of BMS)
  • Inovio Pharmaceuticals
  • Institut de Veille Sanitaire (InVS) [France]
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
  • Institut National de la Santé et de la Recherche Médicale (INSERM) [France]
  • InterMune
  • J&J
  • Janssen Pharmaceutica (a subsidiary of J&J)
  • Kadmon Pharmaceuticals
  • Kun Run Biotechnology
  • LG Life Sciences
  • Maxwell Biotech Venture Fund
  • Medgenics
  • Medivir
  • Medtronic
  • Merck & Co.
  • Minapharm Pharmaceuticals
  • Ministry of Health [China]
  • Ministry of Health, Labor and Welfare (MHLW) [Japan]
  • Mitsubishi Tanabe Pharma
  • MYR
  • Nanogen Biopharmaceutical
  • Natco Pharma
  • National Health Service (NHS) [UK]
  • National Institute for Health and Clinical Excellence (NICE) [UK]
  • National Institutes of Health (NIH) [US]
  • Novartis
  • OctoPlus
  • Okairos
  • Oxford University
  • Pharmasset (now part of Gilead)
  • Quest Diagnostics
  • Ranbaxy Laboratories
  • Reliance Life Sciences
  • REPLICor
  • Rhein Biotech (now part of Dynavax Technologies)
  • Roche
  • Sanofi-Pasteur
  • Schering-Plough (now part of Merck & Co)
  • SciClone Pharmaceuticals
  • Scottish Medicines Consortium (SMC)
  • SCYNEXIS
  • Sigmapharm Laboratories
  • Sinopharm Group
  • State Food and Drug Administration (SFDA) [China]
  • Teva
  • The Vaccine Fund
  • Tibotec Pharmaceuticals (a subsidiary of Janssen Pharmaceutica)
  • Transgene
  • University of Alberta
  • University of Heidelberg
  • Valeant Pharmaceuticals International
  • Vertex Pharmaceuticals
  • ViroChem Pharma (now part of Vertex)
  • Welsh School of Pharmacy (Cardiff University)
  • World Health Organization (WHO)
  • World Hepatitis Alliance
  • Xiamen Innovax Biotech
  • Xiamen University
  • Zuellig Pharma
  • Zydus Cadila
  • ZymoGenetics (now part of BMS)
Show More
Pricing
Get Notified
Email me when related reports are published